Immunochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies

Hybridoma

Volumn 18, Issue 3, 1999, Pages 225-234

  Lukas, Claudia ^a   Jensen, Simon Skjöde ^a   Bartkova, Jirina ^a   Lukas, Jiri ^a   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; MONOCLONAL ANTIBODY; CDK4 PROTEIN, HUMAN; CDK4 PROTEIN, MOUSE; CDK4 PROTEIN, RAT; CDK6 PROTEIN, HUMAN; CDK6 PROTEIN, MOUSE; CDK6 PROTEIN, RAT; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; ONCOPROTEIN; PRIMER DNA; PROTEIN SERINE THREONINE KINASE; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE SECTION; ANIMAL; CELL LINE; CHEMISTRY; ENZYMOLOGY; EPITOPE MAPPING; GENETICS; HYBRIDOMA; IMMUNOCHEMISTRY; IMMUNOLOGY; METABOLISM; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; DNA PRIMERS; EPITOPE MAPPING; HUMANS; HYBRIDOMAS; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICE; MUTATION; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RATS; RETINOBLASTOMA PROTEIN;

EID: 0032586934     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245799315871     Document Type: Article

References (25)

1. Morgan DO: Principles of CDK regulation. Nature 1995;374: 131-134.
2. Lees E: Cyclin dependent kinase regulation. Curr Opin Cell Biol 1995;7:773-780.
3. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 1995;308:697-711.
4. Bartek J, Bartkova J, and Lukas J: The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996;8:805-814.
5. Sherr CJ: Cancer cell cycles. Science 1995;274:1672-1677.
6. Hall M, and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
7. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
8. Bartek J, Bartkova J, and Lukas J: The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997;237:1-6.
9. Vallance SJ, Lee HM, Roussel MF, Shurtleff SA, Kato JY, Strom DK, and Sherr CJ: Monoclonal antibodies to mammalian D-type G1 cyclins. Hybridoma 1994;13:37-44.
10. Lukas J, Pagano M, Stasova Z, Draetta G, and Bartek J: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994;9:707-718.
11. Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, and Bartek J: Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific eel types. Oncogene 1995;10:2125-2134.
12. Bartkova J, Lukas J, Strauss M, and Bartek J: Cyclin D3: Requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998;17:1027-1037.
13. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, and Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375: 503-506.
14. Welcker M, Lukas J, Strauss M, and Bartek J: p21 mutants deficient in inhibiting cyclin-dependent kinases can promote assembly of active cyclin D/Cdk4(6) complexes in human tumor cells. Cancer Res 1998;58:5053-5056.
15. Lukas J, Bartkova J, Rohde M, Strauss M, and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995;15: 2600-2611.
16. Szekely L, Jiang WQ, Bulic-Jakus F, Rosen A, Ringertz N, Klein G, and Wiman KG: Cell type and differentiation dependent heterogeneity in retinoblastoma protein expression in SCID mouse fetuses. Cell Growth Differ 1992;3:149-156.
17. Bartkova J, Lukas J, Strauss M, and Bartek J: Cell cycle-related variation and tissue-restricted expression of human cyclin D1 protein. J Pathol 1994;172:237-245.
18. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P, Strauss M, and Bartek J: DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relive the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994;125:625-638.
19. Coleman KG, Wautlet BS, Morrissey D, Mulheron J, Sedman SA, Brinkley P, Price S, and Webster KR: Identification of CDK4 sequences involved in Cyclin D1 and p16 binding. J Biol Chem 1997;272:18869-18874.
20. Wölfel Y, Hauser M, Schneider J, Serrano M. Wölfel C, Klehmann-Hieb E, De Plaen E, Hankein T, Meyer zum Büschenfelde KH, and Beach D: A p16INK4a-insensitive cdk4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269: 1281-1284.
21. INK4a binding domain of CDK4 in familial melanoma. Nature Genet 1996;12:97-99.
22. Bartkova J, Lukas J, Guldberg P, Alner J, Kirkin AF, Zeuthen J, and Bartek J: The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56:5475-5483.
23. Kip1 coordinate their inhibitory interactions with Cdk4 and Cdk2. Genes Dev 1997;11:492-503.
24. He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day III RS, and James CD: Cdk4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994;54:5804-5807.
25. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su-Huang HJ, and Cavenee WK: Cyclin-dependent kinase 6 (Cdk6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 1997;57:1250-1254.